Abingworth Management Inc Company Profile

06:19 EST 19th December 2018 | BioPortfolio

Abingworth is a long-established venture capital firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage as well as public companies. Abingworth has provided backing for more than 90 unquoted life science businesses.

The majority of these have gone public or have merged or been acquired. Abingworth has funds under management of more than $750 million. Founded in 1973, Abingworth has offices in London, Cambridge (UK), Menlo Park (California) and Boston.

Abingworth’s funds are exclusively dedicated to life sciences. Abingworth’s team has a strong scientific background in addition to business, financial and other specialist skills. These include legal, investment banking, fund-raising as well as operating and recruiting capabilities. These resources are extended to portfolio companies in order to help build successful companies. Abingworth’s team offering is further complemented by a network of scientific and industry consultants who contribute to the process of evaluating new opportunities, creating companies and supporting existing portfolio investments.
This combination of broad-ranging experience and resources enables Abingworth to assist companies at any stage of development, including during and after the IPO process.

Abingworth seeks to invest in the best opportunities in the life sciences market. Investments have been made in platform and enabling technologies, devices and instrumentation as well as in companies developing products in a range of therapeutic areas.

Abingworth’s investments are based in the US and Europe including the UK, Belgium, Denmark, France, Germany, Holland and Sweden. Abingworth’s investments range from $1 to $25 million, averaging around $15 million per investment after all private rounds of financing.


3000 Sand Hill Road Bldg. 4, Suite 135
Menlo Park
United States of America


Phone: 650 926 0600
Fax: 650 926 9782

News Articles [307 Associated News Articles listed on BioPortfolio]

Abingworth Raises €268M to Invest in Life Science Companies

Abingworth has raised $315M (€268M) for its most recent fund, Abingworth Bioventures VII, which invests in European and US life science companies. In the current fundraising, Abingworth surpassed i...

Curating Abingworth

Abingworth seeks double digit returns with its $315M Bioventures VII fund through three investment strategies and an expanded investor base.

SR One’s Brian Gallagher Jumps to Abingworth for Partner Post

Brian Gallagher is joining London-based Abingworth as a partner based in the life sciences investment firm’s Boston office. Gallagher comes to Abingworth from SR One, the venture capital arm of Glax...

Abingworth Closes 12th Life Sciences Fund ABV VII At $315M

European biotechs are likely to be the big winner as transatlantic VC Abingworth closes its latest fund, Abingworth Ventures VII...    

Management tracks: Garland to lead Portola; Gallagher joining Abingworth

Abingworth Closes on $315 Million Fund Aimed at Life Science Companies in Europe and the U.S.

Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and t...

Abingworth appoints Brian Gallagher as Partner

Abingworth closes new biotech fund at €268m

PubMed Articles [1788 Associated PubMed Articles listed on BioPortfolio]

Supporting self-management in palliative care throughout the cancer care trajectory.

Despite increased survivorship and the subsequent need for chronic management of cancer, the association of self-management and palliative care is still emerging within cancer care. Routine and timely...

ICU Management of Trauma Patients.

To describe the current state of the art regarding management of the critically ill trauma patient with an emphasis on initial management in the ICU.

mHealth Applications: A Tool for Behaviour Change in Weight Management.

Obesity has become a public concern all over the world and weight management is of interest to consumers. Heavy intake of food and lack of exercise are the foremost factors for obese condition. Self-m...

Are fishery management upgrades worth the cost?

Many analyses of fishery recovery have demonstrated the potential biological and economic benefits of management reform, but few have compared these to the associated costs of management upgrades, whi...

The Dermal Exposure Risk Management and Logic eTookit: Characterizing and managing dermal exposure during emergency management operations.

Emergency management and operations (EMO) personnel require up-to-date information to make informed decisions during natural and man-made disasters. However, information gaps present challenges for ac...

Clinical Trials [2602 Associated Clinical Trials listed on BioPortfolio]

Hepatitis C Self-Management

The objective of this study is to compare the efficacy of a 6-session hepatitis C self-management workshop to a hepatitis C self-management self-study program. Both interventions are desig...

Contingency Management Treatment Duration

310 alcohol abusing or dependent patients beginning intensive outpatient day treatment at community-based clinics will be randomly assigned to one of four conditions: (a) standard treatmen...

Allo - Cancer - Thrombosis

Management of venous thromboembolism (VTE) in patients with cancer is complex and require the intervention of many specialized health professionals, in hospital but also at home and during...

Clinical Outcomes From Patient Self-management of Antivitamin K Treatment

ORION is a retrospective, observational, one center study to evaluate the incidence of complications (both thromboembolic and bleedings) in a cohort of patients receiving Vitamin K antagon...

Self-care Management Program for Dry Eye Disease Patients Using the heiQ

Dry Eye Disease (DED)is a chronic disease without a cure. Empowering patients to engage in better self-care requires knowledge of their disease and skills in self-management, which can lea...

Companies [1228 Associated Companies listed on BioPortfolio]

Abingworth Management Ltd

Abingworth is a vital player among life science venture capital investors on both sides of the Atlantic, with offices in London and Palo Alto. Abingworth has funds under management of over $300 millio...

Abingworth Management Inc

Abingworth is a long-established venture capital firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage a...

Virion Biotherapeutics

Virion Biotherapeutics seeks to transform the management of respiratory viral infections with the development of its proprietary Therapeutic Interfering Particles (TIPs). These fi...

Avila Therapeutics, Inc.

Avila focuses on design and development of targeted covalent drugs to achieve best-in-class outcomes that cannot be achieved through traditional chemistries. This approach is call...

Intellikine, Inc.

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start ...

More Information about "Abingworth Management Inc" on BioPortfolio

We have published hundreds of Abingworth Management Inc news stories on BioPortfolio along with dozens of Abingworth Management Inc Clinical Trials and PubMed Articles about Abingworth Management Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Abingworth Management Inc Companies in our database. You can also find out about relevant Abingworth Management Inc Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record